0000910329FALSE00009103292023-06-142023-06-140000910329exch:XNYS2023-06-142023-06-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2023
MEDIFAST, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other
jurisdiction of incorporation)
001-31573
(Commission
File Number)
13-3714405
(I.R.S. Employer
Identification No.)
100 International Drive, Baltimore, Maryland 21202
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (410) 581-8042
N/A
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, par value $0.001 per share
MED
New York Stock Exchange
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o



Item 5.07.    Submission of Matters to a Vote of Security Holders.

On June 14, 2023, Medifast, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below.

(i) The number of shares voted and broker non-votes for the directors nominated for re-election to the Board are set forth below.

Director NameForAgainstAbstainedBroker Non-Votes
Jeffrey J. Brown7,690,887234,23230,2521,059,866
Daniel R. Chard7,656,983278,79719,5911,059,866
Elizabeth A. Geary7,849,71077,81227,8491,059,866
Michael A. Hoer7,846,69181,21127,4691,059,866
Scott Schlackman7,810,395117,61627,3601,059,866
Andrea B. Thomas7,387,316532,63435,4211,059,866
Ming Xian7,542,094385,08828,1891,059,866

Accordingly, each of the individuals listed above was elected to the Company’s Board of Directors, each to hold office until the Company’s next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.

(ii) The stockholders voted on a proposal to ratify the appointment of RSM US LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2023.

The proposal was approved by a vote of stockholders as follows:

For:8,949,489
Against:55,282
Abstained:10,466

(iii) The stockholders voted on a proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the proxy statement for the Annual Meeting.

The proposal was approved by a vote of the stockholders as follows:

For:7,495,497
Against:372,673
Abstained:87,201
Broker Non-Votes:1,059,866

(iv) The stockholders voted on a proposal to approve, on an advisory basis, a frequency of one-year of the advisory vote on executive compensation.

The proposal was approved for an annual vote by a vote of the stockholders as follows:



Once Every Year:7,528,144
Once Every 2 Years:36,611
Once Every 3 Years:354,240
Abstained:36,377
Broker Non-Votes:1,059,865

Based upon the results set forth above, and consistent with the Board's recommendation, the Company will hold annual Say-on-Pay votes until the next required advisory vote on frequency of such votes.
Item 8.01.    Other Events.

On June 15, 2023, Company issued a press release announcing the declaration of a cash dividend by the Company's Board of Directors. The full text of the press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated by reference herein.

Item 9.01.    Financial Statements and Exhibits.
(d)
Exhibits.
99.1
104.1Cover Page Interactive Data File (embedded within the Inline XBRL Document)


Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDIFAST, INC.
By:/s/ James P. Maloney
James P. Maloney
Chief Financial Officer
Dated: June 15, 2023

Grafico Azioni Medifast (NYSE:MED)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Medifast
Grafico Azioni Medifast (NYSE:MED)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Medifast